An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy

BACKGROUND: As the most common form of lymphoma, diffuse large B-cell lymphoma (DLBCL) is a clinical highly heterogeneous disease with variability in therapeutic outcomes and biological features. It is a challenge to identify of clinically meaningful tools for outcome prediction. In this study, we d...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jinglei, Xu, Jing, Yu, Muqiao, Gao, Yongchao, Liu, Rong, Zhou, Honghao, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106727/
https://www.ncbi.nlm.nih.gov/pubmed/32228625
http://dx.doi.org/10.1186/s12967-020-02311-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106727/
https://www.ncbi.nlm.nih.gov/pubmed/32228625
http://dx.doi.org/10.1186/s12967-020-02311-1

Ejemplares similares